Visceral adipose tissue is associated with increased cardiometabolic risks including insulin resistance, atherogenic dyslipidaemia, hypertension, inflammation, and coronary heart disease (32), and visceral fat reduction may be one mechanism to explain the benefits seen on cardiovascular outcomes in trials with GLP1-RA among patients with T2D (33). The gene discussed is GLP1R; the disease is coronary artery disorder.